Internal medicine

Sedation

Prostatic urethra

Urinary retention

Quality of life (healthcare)

Prostate cancer

Cancer

Interquartile range

Urology

Nursing

Surgery

Prospective cohort study

International Prostate Symptom Score

Prostate

Lower urinary tract symptoms

Perioperative

Medicine

BJU International

Objectives To report 3‐year follow‐up results of the first implantations with a temporary implantable nitinol device ( TIND ® ; Medi‐Tate Ltd., Or Akiva, Israel) for the treatment of lower urinary tract symptoms ( LUTS ) secondary to benign prostatic hyperplasia ( BPH ). Patients and Methods In all, 32 patients with LUTS were enrolled in this prospective study. The study was approved by the local Ethics Committee. Inclusion criteria were: age &gt;50 years, International Prostate Symptom Score ( IPSS ) ≥10, peak urinary flow ( Q max ) &lt;12 mL/s, and prostate volume &lt;60 mL. The TIND was implanted within the bladder neck and the prostatic urethra under light sedation, and removed 5 days later in an outpatient setting. Demographics, perioperative results, complications (according to Clavien–Dindo classification), functional results, and quality of life (QoL) were evaluated. Follow‐up assessments were made at 3 and 6 weeks, and 3, 6, 12, 24 and 36 months after the implantation. The Student's t ‐test, one‐way analysis of variance and Kruskal–Wallis tests were used for statistical analyses. Results At baseline, the mean (standard deviation, sd ) patient age was 69.4 (8.2) years, prostate volume was 29.5 (7.4) mL, and Q max was 7.6 (2.2) mL/s. The median (interquartile range, IQR ) IPSS was 19 (14–23) and the QoL score was 3 (3–4). All the implantations were successful, with a mean total operative time of 5.8 min. No intraoperative complications were recorded. The change from baseline in IPSS , QoL score and Q max was significant at every follow‐up time point. After 36 months of follow‐up, a 41% rise in Q max was achieved (mean 10.1 mL/s), the median ( IQR ) IPSS was 12 (6–24) and the IPSS QoL was 2 (1–4). Four early complications (12.5%) were recorded, including one case of urinary retention (3.1%), one case of transient incontinence due to device displacement (3.1%), and two cases of infection (6.2%). No further complications were recorded during the 36‐month follow‐up. Conclusions The extended follow‐up period corroborated our previous findings and suggests that TIND implantation is safe, effective and well‐tolerated, for at least 36 months after treatment.

3‐Year follow‐up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction